OptiBiotix Health PLC (LON:OPTI) has announced the appointment of Mikkel Hvid-Hansen as European Sales Leader of its wholly-owned subsidiary, ProBiotix Health Ltd.
The life sciences business – which is developing compounds to tackle obesity, high cholesterol, diabetes and skincare – noted that Hvid-Hansen is joining ProBiotix Health from a position as International Sales Manager from Cell Biotech Int., a Korean probiotic company selling bulk ingredients and finished products internationally.
Prior to joining Cell Biotech, it added, he spent six years as International Sales Manager at Bifodan where he had responsibility for the sales of several probiotic OTC drugs, and, previously, he also worked for Lallemand, the world's third-largest probiotic company (1998-2006) and Eraco (1995-1998).
The company said Hvid-Hansen will be based in Denmark to support existing sales in Europe and extend the market opportunities for its LPLDL product within the European probiotic supplement, food, and dairy markets.
Steve Prescott, CEO of ProBiotix Health, commented: "Mikkel's experience and track record of launching new products and growing sales within Europe brings over 20 years of commercial and probiotic industry expertise to OptiBiotix's wholly-owned probiotic subsidiary, ProBiotix Health Ltd.
“His network of contacts provides access to key customers which we hope will continue to drive revenue growth of LPLDL in supplement, food and pharmaceutical products around the world.
ProBiotix Health was created to develop science-based healthy bacteria called probiotics to reduce cardiovascular risk. Independent clinical studies have shown its LPLDL probiotic can reduce key cardiovascular risk markers such as total cholesterol, LDL (bad) cholesterol, and blood pressure by up to 36.7%, 13.9% and 5.1% respectively.